ANI Pharmaceuticals ANIP Unrealized Gain (Loss) on Equity Securities

Segments

Generics and Other$0—

Rare Disease and Brands$0—

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Market cap$1.88B+18.3%

Enterprise value$1.87B+5.8%

P/E20.4×—

P/S2×-0.3×

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×